To include your compound in the COVID-19 Resource Center, submit it here.

Cirius safety

How Cirius’ insulin sensitizer could avoid AEs of Actos, Avandia in NASH

Cirius Therapeutics Inc. is developing a second-generation insulin sensitizer for non-alcoholic steatohepatitis that is designed to avoid cardiovascular symptoms and edema associated with first-generation agents.

Insulin-sensitizing thiazolidinediones (TZDs) including Actos pioglitazone from Takeda Pharmaceutical Co. Ltd. and Avandia rosiglitazone from GlaxoSmithKline plc are approved to treat Type II diabetes. Because clinical studies have shown the drugs reduce fibrosis in NASH patients, they are often used off-label to treat NASH. However, widespread use of TZDs is limited

Read the full 754 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE